Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder
Journal of Psychoactive Drugs August 5, 2026 Catherine S. Hwang, David C. Cameron, Allison O’Neill et al.
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy has emerged as a potential strategy to treat posttraumatic stress disorder (PTSD). We conducted a national serial cross-sectional study of U.S. Veterans with PTSD from January 1, 2018, to December 31, 2023, to quantify the prevalence of potential contraindications, risk factors, and drug-drug interactions relevant to MDMA-assisted...